RT Journal Article
SR Electronic
T1 Blood-based epigenome-wide analyses of chronic low-grade inflammation across diverse population cohorts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.02.23298000
DO 10.1101/2023.11.02.23298000
A1 Hillary, Robert F.
A1 Ng, Hong Kiat
A1 McCartney, Daniel L.
A1 Elliott, Hannah R.
A1 Walker, Rosie M.
A1 Campbell, Archie
A1 Huang, Felicia
A1 Direk, Kenan
A1 Welsh, Paul
A1 Sattar, Naveed
A1 Corley, Janie
A1 Hayward, Caroline
A1 McIntosh, Andrew M.
A1 Sudlow, Cathie
A1 Evans, Kathryn L.
A1 Cox, Simon R.
A1 Chambers, John C.
A1 Loh, Marie
A1 Relton, Caroline L.
A1 Marioni, Riccardo E.
A1 Yousefi, Paul D.
A1 Suderman, Matthew
YR 2023
UL http://medrxiv.org/content/early/2023/11/03/2023.11.02.23298000.abstract
AB Chronic inflammation is a hallmark of ageing and age-related disease states. The effectiveness of inflammatory proteins such as C-reactive protein (CRP) in assessing long-term inflammation is hindered by their phasic nature. DNA methylation (DNAm) signatures of CRP may act as more reliable markers of chronic inflammation. We show that inter-individual differences in DNAm capture 50% of the variance in circulating CRP (N=17,936, Generation Scotland). We develop a series of DNAm predictors of CRP using state-of-the-art algorithms. An elastic net regression-based predictor outperformed competing methods and explained 18% of phenotypic variance in the LBC1936 cohort, doubling that of existing DNAm predictors. DNAm predictors performed comparably in four additional test cohorts (ALSPAC, HELIOS, SABRE, LBC1921), including individuals of diverse genetic ancestry and from different age groups. The newly-described predictor surpassed assay-measured CRP and a genetic score in its associations with 26 health outcomes. Our findings forge new avenues for assessing chronic low-grade inflammation in diverse populations.Competing Interest StatementR.F.H. and R.E.M. act as scientific consultants for Optima Partners. R.E.M. is an advisor to the Epigenetic Clock Development Foundation. R.F.H. has received consultant fees from Illumina. P.W. reports grant income from Roche Diagnostics in relation to and outside of the submitted work, as well as grant income from AstraZeneca, Boehringer Ingelheim, and Novartis, outside the submitted work and speaker fees from Novo Nordisk, and Raisio outside the submitted work. N.S. has consulted for Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work. All other authors declare no competing interests.Funding StatementThis research was funded in whole, or in part, by Wellcome [104036/Z/14/Z, 220857/Z/20/Z, 217065/Z/19/Z, 067100, 37055891, 086676/7/08/Z, 221890/Z/20/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. We are extremely grateful to all participants, team members and support staff in GS, HELIOS, SABRE and the LBCs for their invaluable contributions to this study. Further, for ALSPAC, we are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. GS received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Genotyping and DNA methylation profiling of the GS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, Edinburgh, Scotland, and was funded by the Medical Research Council UK and Wellcome (Wellcome Trust Strategic Award STratifying Resilience and Depression Longitudinally [STRADL; Reference 104036/Z/14/Z]). The DNA methylation data assayed for GS was partially funded by Wellcome [220857/Z/20/Z], a 2018 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation [27404; awardee: Dr David M Howard] and by a JMAS SIM fellowship from the Royal College of Physicians of Edinburgh [Awardee: Dr Heather C Whalley]. Roche Diagnostics supported this study through provision of free reagents and a grant for measurement of CRP in GS. We thank Elaine Butler, Ross Hepburn, and Ellen Macdonald, University of Glasgow, for excellent technical support. The UK Medical Research Council and Wellcome [217065/Z/19/Z] and the University of Bristol provided core support for ALSPAC. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). Methylation data in the ALSPAC cohort were generated as part of the UK BBSRC-funded [BB/I025751/1, BB/I025263/1] Accessible Resource for Integrated Epigenomic Studies (ARIES, https://www.ariesepigenomics.org.uk). The ALSPAC study was further supported by the National Institute for Health and Care Research Bristol Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The HELIOS study was supported by the Singapore Ministry of Healths National Medical Research Council under its OF–LCG funding scheme [MOH–000271–00] and intramural funding from Nanyang Technological University, Lee Kong Chian School of Medicine and the National Healthcare Group of Singapore. SABRE was supported at baseline by the Medical Research Council, the British Heart Foundation and Diabetes UK. At follow–up, the SABRE study was funded by Wellcome [067100, 37055891, 086676/7/08/Z], the British Heart Foundation [PG/06/145, PG/08/103/26133, PG/12/ 29/29497, CS/13/1/30327] and Diabetes UK [13/0004774]. The SABRE study team also acknowledges the support of the National Institute of Health Research Clinical Research Network [NIHRCRN]. The LBC1936 is jointly core–funded by the Biotechnology and Biological Sciences Research Council and the Economic and Social Research Council [BB/W008793/1], and received support from Age UK (Disconnected Mind programme), the Milton Damerel Trust, the Medical Research Council [MR/M01311/1] and the University of Edinburgh. LBC1921 data collection was supported by grants from the Biotechnology and Biological Sciences Research Council [15/SAG09977] and the Chief Scientist Office of the Scottish Executive Health Department [CZB/4/505, ETM/55, CZH/4/213, CZG/3/2/79]. Methylation typing was supported by the Centre for Cognitive Ageing and Cognitive Epidemiology (Pilot Fund award), Age UK, The Wellcome Trust Institutional Strategic Support Fund, The University of Edinburgh, and The University of Queensland. R.F.H. is supported by a British Heart Foundation Immediate Fellowship [FS/IPBSRF/22/27042]. H.R.E. is supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol [MC_UU_00011/5]. F.H. and K.D. were supported within a Unit that received support from the UK Medical Research Council [MC_UU_12019/1]. S.R.C. was supported by a Sir Henry Dale Fellowship jointly funded by Wellcome and the Royal Society [221890/Z/20/Z]. R.E.M. is supported by an Alzheimers Society major project grant [AS–PG–19b–010]. P.D.Y. and M.S. are supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol [MC_UU_00011/5] and Cancer Research UK [C18281/A29019]. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Generation Scotland All components of Generation Scotland received ethical approval from the NHS Tayside Committee on Medical Research Ethics [REC Reference Number: 05/S1401/89]. Generation Scotland has also been granted Research Tissue Bank status by the East of Scotland Research Ethics Service [REC Reference Number: 20–ES–0021], providing generic ethical approval for a wide range of uses within medical research. All participants provided written informed consent. ALSPAC Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). HELIOS The HELIOS study was approved by the National Technological University (NTU) Institutional Review Board [IRB–2016–11–030], with written informed consent obtained from each participant before the commencement of the study. SABRE The SABRE study was approved by St Marys Hospital Research Ethics Committee [07/H0712/109] and all participants provided written informed consent. Lothian Birth Cohort 1936 Ethical approval was obtained from the Multicentre Research Ethics Committee for Scotland (age 70, [MREC/01/0/56]), the Lothian Research Ethics Committee (age 70, [LREC/2003/2/29]), and the Scotland A Research Ethics Committee (ages 73, 76, 79, 82, [07/MRE00/58]). All participants provided written informed consent. Lothian Birth Cohort 1921 Ethical approval was provided by the Lothian Research Ethics Committee for test waves 1–3 at ages 79, 83 and 87 [LREC/1998/4/183, LREC/2003/7/23, 1702/98/4/183] and the Scotland A Research Ethics Committee for test wave 4 at age 90 [10/MRE00/87, 10/MRE00/87]. All participants provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAccording to the terms of consent for GS participants, access to data must be reviewed by the GS Access Committee. Applications should be made to access{at}generationscotland.org. ALSPAC data access is through a system of managed open access. Submissions and queries should be directed to alspac-data{at}bristol.ac.uk. For HELIOS, data access request proposals should be directed to helios_science{at}ntu.edu.sg for the consideration of the HELIOS Studys principal investigators. SABRE data used for this submission will be made available on request to mrclha.swiftinfo{at}ucl.ac.uk. Further details regarding data sharing can be found on the cohort web pages (https://www.sabrestudy.org/home-2/data-sharing/). Lothian Birth Cohort data access requests can be made by following the information at https://www.ed.ac.uk/lothian-birth-cohorts/data-access-collaboration. Epigenome–wide association statistics from linear models will be made available at the EWAS Catalog [URL to follow at publication]. Epigenome–wide association statistics from Bayesian penalised regression will be made available at the University of Edinburgh Datashare site [URL to follow at publication]. CpGs and weights derived from elastic net regression, Bayesian penalised regression and the combined PCA and elastic net regression strategies will also be available at the Edinburgh Datashare site [URL to follow at publication]. CpGs and weights for the elastic net regression and PCA+elnet–based approaches from this version of the manuscript are available in Additional file 2: Tables S3 and S4. The Bayesian penalised regression predictor is not made available in Additional file 2 due to the large number of CpGs involved (>300,000). All code associated with this manuscript, including scripts to project DNAm CRP into test samples, is available open access at the following GitHub repository: https://github.com/robertfhillary/dnam-crp.